News ReleaseView printer-friendly version
Quidel Executives Invited by HHS Secretary Thompson and FDA Commissioner McClellan to Participate in Meeting on Developing Diagnostic Tests for SARS
SAN DIEGO, Calif.--(BUSINESS WIRE)--June 3, 2003--S. Wayne Kay, president and chief executive officer of Quidel Corporation (Nasdaq:QDEL), and Paul J. Lawrence, Ph.D., chief technology officer, attended a meeting called by Tommy G. Thompson, Secretary of Health and Human Services, U.S. Department of Health and Human Services (HHS), and Mark B. McClellan, M.D., Ph.D., Commissioner of Food and Drugs, U.S. Food and Drug Administration (FDA), to discuss development of diagnostic tests for Severe Acute Respiratory Syndrome (SARS) held May 29 in Washington, D.C.
In addition to Secretary Thompson and Commissioner McClellan, participating in the meeting were additional representatives from HHS, FDA and the Centers for Disease Control and Prevention (CDC), as well as executives from eight other companies involved in human medical diagnostics.
The meeting was called to communicate the Secretary's and the Department's interest in the development of accurate, inexpensive and rapid diagnostic tests for SARS; to allow industry representatives to present their views of impediments to getting quality SARS diagnostics developed, approved and marketed as quickly as possible; to allow HHS to hear what industry thinks the office of the Secretary, FDA and CDC could do to address these issues and to discuss next steps that are needed to undertake to accomplish the stated goal.
"Quidel was honored to be included in this prestigious gathering of federal government and industry leaders, and we support Secretary Thompson's and Commissioner McClellan's goals of the rapid development of accurate, inexpensive and fast diagnostic tests for SARS," commented S. Wayne Kay. "We found this meeting to be an extremely valuable and insightful initial step in developing a working partnership between the public and private sectors in pursuit of this goal, and we look forward to further strategic review of this opportunity within Quidel to determine our potential role."
According to the CDC, "SARS likely is to be a disease we will face for some time, and there is a pressing need for a SARS diagnostic test." According to Dr. Lawrence, "We face various technical hurdles in developing such a test, including access to quality clinical specimens or reagents, and the ability to identify patients with co-infection including, for example, influenza, chlamydia and/or yersinia pestis."
For additional information on the meeting, please contact the HHS press office at (202) 690-6343. Additional information on SARS is available at www.cdc.gov/ncidod/sars/
Quidel Corporation, a worldwide company helping women and their families live healthy lives, discovers, develops, manufactures and markets rapid point-of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, Strep throat, H. pylori infection, chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information that enables rapid treatment and improves health outcomes, lowers costs and increases patient satisfaction. For more information, please visit Quidel's Web site at www.quidel.com.
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risk and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in operating results may arise as a result of a number of factors including, without limitation, seasonality, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the FDA and the lower acceptance of our new products than forecast. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" and in other sections of our Form 10-K for year ended December 31, 2001, and in other reports and registration statements that we file with the Securities and Exchange Commission from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this presentation. We undertake no obligation to publicly release the results of any revision of the forward-looking statements.
CONTACT: Quidel Corporation
Paul E. Landers, 858/552-7962
Lippert/Heilshorn & Associates
Ina McGuinness (email@example.com)
Bruce Voss (firstname.lastname@example.org)
SOURCE: Quidel Corporation